Most people know ByteDance for Douyao (豆包), the chatbot, and Douyin (抖音), the short-video app. Less visible is what the company did with its drug-discovery team: it carved that group out entirely, and the spinoff just pulled in a serious first check from outside investors.
A new company, a real valuation
On September 16, 2026, Reuters reported that Anew Labs — a Shanghai-based unit using AI for drug discovery — had closed its first external funding round at US$290 million, with a post-money valuation of about US$1.5 billion. ByteDance keeps a 56% stake after the raise.
The round was led by HSG (formerly Sequoia China), IDG Capital, and GL Ventures (the venture arm of Hillhouse Investment), with 5Y Capital as co-lead. Other backers included Gaorong Ventures, Primavera Venture Partners, Boyu Capital, strategic investor SBP Group, and the state-backed Shanghai Future Industries Fund. ByteDance and the investors did not immediately comment; the figures come from people familiar with the matter.
Why spin it off at all?
The logic is structural, not cosmetic. AI drug discovery runs on a completely different clock and risk profile than an advertising or consumer-app business. Clinical trials take years, failure rates are high, and the talent and capital needs don't map onto how ByteDance runs TikTok. By separating Anew Labs, the team can raise science-specific capital, recruit researchers on startup terms, and be valued on pipeline potential rather than bundled inside a US$300B+ internet empire.
Anew Labs is not a lab in name only. Its website lists platforms for biomolecular structure prediction and design, antibody optimization, and discovery — including AnewOmni for molecular modeling and AnewSampling for molecular dynamics. Its pipeline includes a small-molecule drug, a candidate targeting a protein on human cell surfaces, and two undisclosed targets. One lead, AN-5162, an IL-17 inhibitor in preclinical stage, was disclosed at a Boston immunology meeting in April.
The bigger pattern
This is part of a wider move: China's large tech groups are unbundling their AI science bets so each can raise on its own merits.
- Isomorphic Labs (DeepMind spinout) raised US$2.1B in May 2026.
- Chai Discovery (US) raised US$400M at US$3.8B in July 2026.
- The field is still pre-clinical at scale: by mid-2026 there were roughly 180 AI-originated drug pipelines globally, only about a dozen in Phase III, and zero FDA-approved AI-discovered drugs.
In other words, the money is buying an option on a hard problem — not a near-term product. Anew Labs outsources wet-lab work to contract research organizations and runs compute on Volcano Engine, keeping its own team focused on algorithms and people.
What readers can do now
- Watch the spinoffs, not just the chatbots. When a giant like ByteDance carves out an AI-science unit and raises outside money, that unit's hiring, partnerships, and pipeline disclosures become a cleaner signal than anything buried in a parent's earnings call.
- Track the lead asset. AN-5162's move toward an investigational-new-drug filing (reportedly targeted for Q4 2026) is the first concrete milestone to watch — preclinical claims are cheap, IND submissions are not.
- Benchmark against global peers. Compare Anew Labs' US$1.5B mark against Isomorphic (US$2.1B) and Chai (US$3.8B) to gauge how capital is pricing China vs. US AI-drug platforms.
Honest limitations
The funding amount, valuation, investor list, and ByteDance's retained stake are drawn from Reuters reporting citing two people familiar with the matter; ByteDance and the named investors did not comment, so none of these figures are company-confirmed. Pipeline details (AN-5162, platform names) come from Anew Labs' own website and secondary coverage, not from peer-reviewed publications or regulatory filings. There is no disclosed revenue, no clinical asset yet in trials, and no independent verification of the platforms' wet-lab performance. Treat the US$1.5B valuation as a reported funding-mark, not an audited enterprise value.